Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
- 1 May 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 25 (5), 738-+
- https://doi.org/10.1038/s41591-019-0380-z
Abstract
Next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) supports blood-based genomic profiling but is not yet routinely implemented in the setting of a phase I trials clinic. TARGET is a molecular profiling program with the primary aim to match patients with a broad range of advanced cancers to early phase clinical trials on the basis of analysis of both somatic mutations and copy number alterations (CNA) across a 641 cancer-associated-gene panel in a single ctDNA assay. For the first 100 TARGET patients, ctDNA data showed good concordance with matched tumor and results were turned round within a clinically acceptable timeframe for Molecular Tumor Board (MTB) review. When a 2.5% variant allele frequency (VAF) threshold was applied, actionable mutations were identified in 41 of 100 patients, and 11 of these patients received a matched therapy. These data support the application of ctDNA in this early phase trial setting where broad genomic profiling of contemporaneous tumor material enhances patient stratification to novel therapies and provides a practical template for bringing routinely applied blood-based analyses to the clinic.This publication has 30 references indexed in Scilit:
- Prediction and Prioritization of Rare Oncogenic Mutations in the Cancer Kinome Using Novel Features and Multiple ClassifiersPLoS Computational Biology, 2014
- Ceritinib inALK-Rearranged Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2014
- Liquid Biopsies: Genotyping Circulating Tumor DNAJournal of Clinical Oncology, 2014
- Clinical Analysis and Interpretation of Cancer Genome DataJournal of Clinical Oncology, 2013
- Characteristics of Lung Cancers Harboring NRAS MutationsClinical Cancer Research, 2013
- Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencingGenome Medicine, 2013
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Harnessing the Power of Default Options to Improve Health CareThe New England Journal of Medicine, 2007
- Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)Annals of Oncology, 2005